Abbvie Company Profile

✉ Email this page to a colleague

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has one hundred and thirty-eight approved drugs.

There are two hundred and twenty-nine US patents protecting ABBVIE drugs.

There are two thousand seven hundred and twenty-eight patent family members on ABBVIE drugs in sixty-six countries and three hundred and ninety-five supplementary protection certificates in nineteen countries.

Summary for Abbvie

International Patents:	2728
US Patents:	229
Tradenames:	124
Ingredients:	99
NDAs:	138
Drug Master File Entries:	1
Patent Litigation for Abbvie:	See patent lawsuits for Abbvie

Drugs and US Patents for Abbvie

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium; ombitasvir, paritaprevir, ritonavir	TABLET;ORAL	206619-001	Dec 19, 2014		DISCN	Yes	No	8,501,238	⤷ Sign Up	Y	Y		⤷ Sign Up
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-002	Dec 15, 1995	AP	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Abbvie	FML	fluorometholone	SUSPENSION/DROPS;OPHTHALMIC	016851-002	Jul 28, 1982	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015		RX	Yes	No	9,364,489	⤷ Sign Up				⤷ Sign Up
Abbvie	MAVYRET	glecaprevir; pibrentasvir	PELLETS;ORAL	215110-001	Jun 10, 2021		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Abbvie	UBRELVY	ubrogepant	TABLET;ORAL	211765-002	Dec 23, 2019		RX	Yes	Yes	8,912,210	⤷ Sign Up	Y	Y		⤷ Sign Up
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-002	Sep 28, 2021		RX	Yes	No	10,117,836	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Abbvie

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Endocrine	LUPANETA PACK	leuprolide acetate; norethindrone acetate	INJECTABLE, TABLET;INTRAMUSCULAR, ORAL	203696-001	Dec 14, 2012	6,036,976	⤷ Sign Up
Abbvie	COMBIGAN	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021398-001	Oct 30, 2007	7,642,258	⤷ Sign Up
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020708-001	Mar 7, 1997	5,716,640	⤷ Sign Up
Abbvie	DEPAKOTE ER	divalproex sodium	TABLET, EXTENDED RELEASE;ORAL	021168-002	May 31, 2002	4,988,731*PED	⤷ Sign Up
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-001	Aug 14, 2002	RE34712*PED	⤷ Sign Up
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-007	Aug 15, 2011	5,631,020	⤷ Sign Up
Abbvie	ORILISSA	elagolix sodium	TABLET;ORAL	210450-002	Jul 23, 2018	7,179,815	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ABBVIE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-23
➤ Subscribe	Extended-release Tablets	500 mg	➤ Subscribe	2005-02-08
➤ Subscribe	Capsules	7 mg/10 mg	➤ Subscribe	2016-09-26
➤ Subscribe	Ophthalmic Solution	0.10%	➤ Subscribe	2006-12-20
➤ Subscribe	Extended-release Tablets	2 mg/180 mg and 2 mg/240 mg	➤ Subscribe	2007-11-09
➤ Subscribe	Oral Solution	80 mg/20 mg per mL	➤ Subscribe	2014-06-19
➤ Subscribe	Ophthalmic Solution	0.2%/0.5%	➤ Subscribe	2008-11-21
➤ Subscribe	Extended-release Tablets	4 mg/ 240 mg	➤ Subscribe	2007-07-24
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2010-12-21
➤ Subscribe	Ophthalmic Solution	0.03%	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	1 mg, 2 mg and 4 mg	➤ Subscribe	2004-10-04
➤ Subscribe	Injection	0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials	➤ Subscribe	2008-11-28
➤ Subscribe	Ophthalmic Solution	0.5%	➤ Subscribe	2010-12-07
➤ Subscribe	Delayed-release Capsules	45 mg	➤ Subscribe	2009-09-02
➤ Subscribe	Tablets	12.5 mg, 25 mg, 50 mg, and 100 mg	➤ Subscribe	2013-01-14
➤ Subscribe	Capsules	4 mcg	➤ Subscribe	2008-08-25
➤ Subscribe	Capsules	5 mg	➤ Subscribe	2005-08-17
➤ Subscribe	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg	➤ Subscribe	2017-07-25
➤ Subscribe	Tablets	48 mg	➤ Subscribe	2008-07-01
➤ Subscribe	Gel	10%	➤ Subscribe	2014-06-19
➤ Subscribe	Injection	10 mg/mL (2 mL)	➤ Subscribe	2018-07-13
➤ Subscribe	Extended-release Capsules	28 mg	➤ Subscribe	2013-06-12
➤ Subscribe	Tablets	2.5 mg/200 mg	➤ Subscribe	2006-02-24
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2009-08-12
➤ Subscribe	Delayed-release Tablets	800 mg	➤ Subscribe	2011-07-13
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-06-10
➤ Subscribe	Tablets	10 mg, 20 mg, and 40 mg	➤ Subscribe	2015-01-21
➤ Subscribe	Ophthalmic Solution	0.40%	➤ Subscribe	2005-01-28
➤ Subscribe	Extended-release Tablets	250 mg	➤ Subscribe	2004-05-03
➤ Subscribe	Capsules	21 mg/10 mg	➤ Subscribe	2016-09-23
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-24
➤ Subscribe	Extended-release Tablets	7.5 mg and 15 mg	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	100 mg/25 mg	➤ Subscribe	2008-12-23
➤ Subscribe	Ophthalmic Solution	0.15%	➤ Subscribe	2006-11-03
➤ Subscribe	Extended-release Tablets	1 mg/240 mg	➤ Subscribe	2008-02-20
➤ Subscribe	Capsules	145 mcg and 290 mcg	➤ Subscribe	2016-08-30
➤ Subscribe	Ophthalmic Solution	0.25%	➤ Subscribe	2014-07-30
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2017-06-09
➤ Subscribe	Capsules	100 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Ophthalmic Solution	0.01%	➤ Subscribe	2011-04-05
➤ Subscribe	Delayed-release Capsules	400 mg	➤ Subscribe	2014-06-17
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Capsules	1 mcg and 2 mcg	➤ Subscribe	2008-10-14
➤ Subscribe	Topical Solution	0.03%	➤ Subscribe	2010-05-03
➤ Subscribe	Delayed-release Capsules	135 mg	➤ Subscribe	2009-09-01
➤ Subscribe	Tablets	400 mg and 600 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Gel	7.5%	➤ Subscribe	2017-02-13
➤ Subscribe	Capsules	10 mg and 20 mg	➤ Subscribe	2005-03-30
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-08-16
➤ Subscribe	Tablets	145 mg	➤ Subscribe	2007-10-19
➤ Subscribe	Injection	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	➤ Subscribe	2009-08-04
➤ Subscribe	Suppository	1000 mg	➤ Subscribe	2013-05-24
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg	➤ Subscribe	2013-06-17
➤ Subscribe	Tablets	5 mg/200 mg	➤ Subscribe	2005-05-27
➤ Subscribe	Injection	400 mg/vial and 600 mg/vial	➤ Subscribe	2014-10-29
➤ Subscribe	Extended-release Tablet	500 mg	➤ Subscribe	2010-12-06
➤ Subscribe	Capsules	14 mg/10 mg and 28 mg/10 mg	➤ Subscribe	2015-05-18

International Patents for Abbvie Drugs

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Portugal	1725537	⤷ Sign Up
Israel	178040	⤷ Sign Up
Lithuania	3213750	⤷ Sign Up
Hong Kong	1243761	⤷ Sign Up
China	103328478	⤷ Sign Up
Japan	5367946	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2006130174	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Abbvie Drugs

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1534313	2015/071	Ireland	⤷ Sign Up	PRODUCT NAME: AN OCULAR IRRIGATION SOLUTION COMPRISING PHENYLEPHRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND KETOROLAC OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1018 20150728
2176234	SPC/GB17/019	United Kingdom	⤷ Sign Up	PRODUCT NAME: ELUXADOLINE; REGISTERED: UK EU/1/16/1126/001(NI) 20160921; UK EU/1/16/1126/002(NI) 20160921; UK EU/1/16/1126/003(NI) 20160921; UK EU/1/16/1126/004(NI) 20160921; UK PLGB 45496/0015 20160921
2368890	300731	Netherlands	⤷ Sign Up	PRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
2618831	17C1039	France	⤷ Sign Up	PRODUCT NAME: GLECAPREVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN ESTER DE CELUI-CI; REGISTRATION NO/DATE: EU/1/17/1213 20170728
0502314	SPC/GB02/037	United Kingdom	⤷ Sign Up	PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
0334429	97C0002	Belgium	⤷ Sign Up	PRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
2435432	386 50008-2017	Slovakia	⤷ Sign Up	PRODUCT NAME: VENETOKLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for Abbvie

Paragraph IV (Patent) Challenges for ABBVIE drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing